Filing excerpt
The decrease in ENBREL sales for the nine months ended September 30, 2026 was driven by lower net selling price of 19% reflecting the ongoing impact of U.S. Medicare Part D price setting effective in 2026 under the IRA, as well as an increase in 340B Program mix, partially offset by favorable changes to estimated sales deductions.